Similarly, cabozantinib potentiated the cytotoxic and anti-tumor effects of topotecan, a well-known substrate for ABCG2, in chemoresistant NSCLC cells in vitro and xenograft models, as well. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.